FDA modernization; genetic privacy

While the negotiations have been "collegial," BIO President Carl Feldbaum said the negotiators have failed to come to terms on how to modify restrictions on dissemination of information about approved products, the most contentious issue under discussion. However, Feldbaum cited FDA's acknowledgment that the policies need to be modified as a sign of significant progress.

The industry/agency negotiations are intended to develop a consensus that

Read the full 647 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE